deferoxamine has been researched along with calcitriol in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Achard, JM; Ben Hamida, F; Bouzernidj, M; el Esjer, N; Fournier, A; Ghazali, A; Morinière, P; Shenovda, M; Westeel, PF | 1 |
| Tzamaloukas, AH | 1 |
| Coburn, JW; Nebeker, HG | 1 |
| Marumo, F; Sato, N; Takahashi, Y; Umetani, N | 1 |
| Aloia, J; Yeh, JK; Zaino, EC | 1 |
| Cronin, RE | 1 |
| Aquino, A; Capobianco, A; Lauriello, F; Pacia, S; Panico, F; Salvati, A; Scoppa, F; Taccone, W; Tedesco, V; Testa, GF | 1 |
| Cannata Andía, JB; Fernández Martín, JL; González Suárez, I; Naves Díaz, M | 1 |
| Hayakawa, H; Hirano, K; Kawamura, Y; Shigematu, T; Yamamoto, I | 1 |
| De Sanctis, V; Fornasari, PM; Fortini, M; Gamberini, MR; Marconi, S; Pratelli, L; Verri, E; Zolezzi, C | 1 |
6 review(s) available for deferoxamine and calcitriol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Use of alkaline calcium salts as phosphate binder in uremic patients.
Topics: Aluminum; Calcinosis; Calcitriol; Calcium; Deferoxamine; Humans; Hyperparathyroidism, Secondary; Phosphates; Renal Dialysis; Uremia | 1992 |
Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients.
Topics: Aluminum; Biopsy; Bone and Bones; Bone Diseases; Calcitriol; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Humans; Kidney Failure, Chronic; Parathyroid Glands; Radiography; Renal Dialysis | 1990 |
Aluminum and renal osteodystrophy.
Topics: 24,25-Dihydroxyvitamin D 3; Aluminum; Animals; Bone and Bones; Calcitriol; Caseins; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Diet; Dihydroxycholecalciferols; Dogs; Drug Therapy, Combination; Humans; Osteomalacia; Parathyroid Hormone; Parenteral Nutrition, Total; Protein Hydrolysates; Rats; Renal Dialysis; Syndrome; Water Supply | 1986 |
Southwestern Internal Medicine Conference: bone disease in kidney failure: diagnosis and management.
Topics: Aged; Biopsy; Bone and Bones; Bone Diseases; Calcitriol; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Contraindications; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Parathyroidectomy; Phosphates; Renal Dialysis | 1993 |
[Therapy for ROD and measurement of the bone mass].
Topics: Absorptiometry, Photon; Bone Density; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Vitamin K 2 | 2004 |
6 other study(ies) available for deferoxamine and calcitriol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
Topics: Aluminum; Bone and Bones; Bone Diseases; Calcitriol; Calcium; Deafness; Deferoxamine; Eye; Humans; Renal Dialysis; Uremia | 1987 |
Defective vitamin D metabolism in thalassemia major.
Topics: Adolescent; Adult; Calcitriol; Calcium; Chelating Agents; Child; Child, Preschool; Deferoxamine; Ergocalciferols; Female; Humans; Hydroxyproline; Iron; Liver; Male; Parathyroid Hormone; Phosphorus; Thalassemia; Vitamin D | 1985 |
[Interaction between active metabolites of vitamin D3 and blood aluminum in chronic uremic patients on dialysis].
Topics: Adolescent; Adult; Aged; Aluminum; Aluminum Hydroxide; Calcitriol; Chronic Disease; Deferoxamine; Drug Interactions; Female; Humans; Hyperparathyroidism, Secondary; Intestinal Absorption; Male; Middle Aged; Renal Dialysis; Tissue Distribution; Uremia | 1993 |
[Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].
Topics: Aluminum; Animals; Bone Neoplasms; Calcitriol; Cattle; Chelating Agents; Culture Media; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Humans; Osteoblasts; Osteocalcin; Osteosarcoma; Pyridones; Secretory Rate; Serum Albumin, Bovine; Tumor Cells, Cultured | 2003 |
Chelation therapy and bone metabolism markers in thalassemia major.
Topics: Adult; Alkaline Phosphatase; beta-Thalassemia; Bone and Bones; Bone Resorption; Case-Control Studies; Chelation Therapy; Cytokines; Deferiprone; Deferoxamine; Female; Humans; Intercellular Signaling Peptides and Proteins; Iron Chelating Agents; Male; Osteocalcin; Osteoporosis; Parathyroid Hormone; Pyridones; Risk Factors; Siderophores; Vitamin D | 2006 |